This article was originally published in The Gray Sheet
AdvaMed sets its sights on achieving a floor vote for product liability reform, given the decreased likelihood of the measure passing with Medicare legislation this year. Rep. Jim Greenwood (R-Penn.) still hopes to attach his HEALTH ACT (HR 5) to the "Medicare Prescription Drug & Modernization Act" of 2003 prior to the House/Senate conference, anticipated after the July 4 recess...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.